Inceptor Bio, a cell therapy biotechnology company, and Avectas, a cell engineering technology leader, have partnered to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.
 
Under the agreement, Inceptor will utilize Avectas’ SOLUPORE technology as an alternative to electroporation for engineering T cells with the goal to yield a healthier T cell product.  Avectas’ SOLUPORE technology is well suited to Inceptor Bio’s CAR-T cell process, which aims to improve the quality of the engineered T cells, and ultimately, enhance their durability in the tumor microenvironment. By combining Avectas’ SOLUPORE delivery with Inceptor Bio’s CAR-T cell therapy platform, the engineered cells have the potential for improved performance and efficacy.
 
Avectas has developed the non-viral SOLUPORE technology to overcome the limitations of current delivery modalities to enable cell engineering, including complex editing, by efficiently delivering cargoes into cells.  SOLUPORE technology permeabilizes the target cell membrane so that molecular cargoes can be delivered while retaining high cell viability and functionality levels.
 
“Inceptor Bio is committed to building and advancing a pipeline of programs based on diversified cell therapies, including CAR-M, CAR-T, and CAR-NK. This collaboration with Avectas is part of our strategy of advancing Inceptor Bio’s next-generation cell therapy platform focused on multiple novel mechanisms to address solid tumors,” said Shailesh Maingi, founder and CEO of Inceptor Bio. “The aim for our proprietary CAR-T platform is to transform how solid tumors are treated.”
 
“Avectas is delighted to collaborate with Inceptor Bio to leverage the benefits of the SOLUPORE delivery platform for solid tumor CAR-T cell therapies,” said Michael Maguire, PhD, CEO of Avectas. “Excellent cell health and functionality, after complex editing, are critical to the success of these next-generation therapies.”